Global Hepatitis E Diagnostic Tests Market Report and Forecast 2024-2032

Global Hepatitis E Diagnostic Tests Market Outlook

The global hepatitis E diagnostic tests market size reached a value of approximately USD 68.34 billion in 2023. The market is further expected to grow at a CAGR of 4.4% between 2024 and 2032, reaching a value of USD 101.01 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Trends in the Market

Hepatitis E is a condition in which the liver becomes inflamed as a result of an infection caused by the Hepatitis E Virus (HEV). Typically, HEV is transmitted through faecal-oral contamination, most often by drinking water contaminated by faecal matter. The diagnostic tests for hepatitis E are based on the detection of anti-HEV immunoglobulins.

• According to the hepatitis E diagnostic tests market analysis, the key trends propelling the growth of the market includes shift towards molecular diagnostics from conventional testing methods. Due to the increase in accuracy and decrease in time required to generate results, the application of molecular diagnostics has significantly increased in the market.

• Growing awareness about the advantages of regularly testing for hepatitis E virus along with selection of right course of treatment in due time is propelling the growth of the market for hepatitis E diagnostic tests. This, in turn, is influencing the hepatitis E diagnostic tests market price across the globe.

• Increasing modernisations and technological advancements in the healthcare sector coupled with growing research and development activities by the key players are positively impacting the growth of the market across the globe. Rising geriatric population along with increasing cases of hepatitis E is another crucial trend in the market for hepatitis E diagnostic tests.

Market Analysis

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

On the basis of test type, the market is segmented into ELISA HEV IgM test, ELISA HEV IgG test, and RT-PCR test. Based on end-use, the market is divided into hospitals, and diagnostic centres, among others. By region, the market is classified into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global hepatitis E diagnostic tests market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.

• MP Biomedicals, LLC

• F. Hoffmann-La Roche Ltd

• Altona Diagnostics GmbH

• AccuBioTech Co., Ltd.

• Dia.Pro Diagnostic Bioprobes s.r.l

• Beijing Wantai

• Fortress Diagnostics

• Mikrogen GmbH.

• Primerdesign Ltd

• Gold Standard Diagnostics

• Others

Market Share by End-Use

According to the hepatitis E diagnostic tests market research, hospitals are expected to account for a major portion of the market for hepatitis E diagnostic tests over the forecast period. This is due to the fact that hospitals are able to integrate diagnostics and treatment with care coordination, which in turn results in faster recovery of the patient. Hospitals are also able to identify potential signs of the virus at an earlier stage, resulting in greater usage of hepatitis E diagnostic tests. Additionally, hospitals are able to provide services such as language assistance, dietary support, and post treatment care, which is contributing towards the growth of the segment in the market for hepatitis E diagnostic tests.

Market Share by Region

In terms of regions, the Asia Pacific holds a significant hepatitis E diagnostic tests market share owing to the heightened prevalence of hepatitis E in East and South Asia. The hyper-endemicity of the condition in the region, worsened by lack of safe drinking water and poor sanitation facilities, are resulting in an increased demand for hepatitis E diagnostic tests. Increasing awareness hepatitis E and overall improved healthcare knowledge are resulting in more people opting for diagnostic tests at earlier signs of symptoms. Heightened population density further increases the risk of spread of hepatitis E, particularly in regions with lack of adequate sanitation. Investments of governments in the region to improve healthcare infrastructure and diagnose and treat prevalent conditions at a faster pace are further supporting the market for hepatitis E diagnostic tests in the Asia Pacific.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

MP Biomedicals, LLC is a biotechnology research company that was established in 1959 and is headquartered in California, United States. Their dedicated team of researchers and scientists is on a quest for ground-breaking discoveries to improve lives and create a better world. The company sells and manufactures over 55,000 products across the globe.

F. Hoffmann-La Roche Ltd is a healthcare company based in Base, Switzerland, that was founded in 1896. The two major divisions of this multinational company are diagnostics and pharmaceuticals, with a wide range of focus areas including cardiometabolic diseases, haematology, infectious diseases, inflammatory bowel diseases, neuroscience, oncology, ophthalmology, rare diseases, and women’s health.

Altona Diagnostics GmbH is a medical diagnostic company that was established in 2007 and is headquartered in Hamburg, Germany. They are involved in the development and manufacture of in-vitro diagnostic tests for detection of viruses, parasites, and bacteria. With over 40 distribution partners, the company’s offerings include instruments and equipment, reagents, and products.

Other market players include AccuBioTech Co., Ltd., Dia.Pro Diagnostic Bioprobes s.r.l, Beijing Wantai, Fortress Diagnostics, Mikrogen GmbH., Primerdesign Ltd, and Gold Standard Diagnostics, among others.

Key Highlights of the Report